Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06680544

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Sheikh Zayed Medical College · Other Government
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

Detailed description

Treatment of dermatophyte infection in our country is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness and feasibility of a newer antifungal drug like voriconazole is the need of the hour in resistant cases. Objective: To compare the efficacy of oral 200 milligram voriconazole once a day vs twice a day in the treatment of resistant dermatophyte infections (tinea corporis and cruris). Material \& Methods: This randomized controlled trial using non-probability sampling technique will be carried out in Outpatient Dermatology Department, Sheikh Zayed Hospital Rahim Yar Khan, Pakistan. Approval from ethical review committee of the hospital has been taken. Total 106 patients will be divided into two groups, Group A and Group B, each consisting of 53 patients. Group A will be given oral voriconazole 200mg once a day and Group B will be given twice a day for a maximum of 28 days. Efficacy will be assessed at day 14 and day 28, and relapse will be noted at the 2-month follow-up visit. Data will be recorded on a preformed Proforma for each patient and wiil be analyzed using SPSS 24. A p-value of less than 0.05 will be considered statistically significant.

Conditions

Interventions

TypeNameDescription
DRUGVoriconazole high doseOral voriconazole 200mg once a day for a maximum of 28 days
DRUGVoriconazole low doseOral voriconazole 200mg twice a day for a maximum of 28 days

Timeline

Start date
2024-11-15
Primary completion
2025-03-01
Completion
2025-03-15
First posted
2024-11-08
Last updated
2024-11-08

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT06680544. Inclusion in this directory is not an endorsement.